Hepatocellular Carcinoma: Who to screen, when, and how?
Hepatocellular carcinoma (HCC) surveillance is a cornerstone of liver disease management, yet uncertainty persists around who to screen, when to initiate surveillance, and which modalities to use. Evolving risk profiles and variation across guidelines have added complexity to clinical decision-making. In this podcast, we revisit the fundamentals of HCC screening, focusing on practical, evidence-based approaches to patient selection, timing, and surveillance strategies.
Host: Mattias Mandorfer (Medical University of Vienna)
Guests: Peter Jepsen (Aarhus University), Amit Singal (UT Southwestern Medical Center)
Prefer to listen on the go? This episode is also available on the following streaming platforms:
Talk Liver To Me is supported by Boehringer Ingelheim, GSK, IPSEN and Opella. Boehringer Ingelheim, GSK, IPSEN and Opella have had no input to the content of this programme.
This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL.
COI - Speakers have reported the following potential conflicts of interest: Mattias Mandorfer: None Peter Jepsen: Honoraria for consulting from AstraZeneca in the field of HCC. Research in HCC is supported by grants from the Independent Research Fund Denmark and the Danish Cancer Society, paid to the speaker’s institution. Research in the broader field of chronic liver disease is supported by a grant from the Novo Nordisk Foundation, paid to the speaker’s institution. Amit Singal: Has served as a consultant or on advisory boards for Genentech, AstraZeneca, Bayer, Eisai, Exelixis, Merck, Elevar, Boston Scientific, Sirtex, Boehringer, Be One, FujiFilm Medical Sciences, Exact Sciences, Helio Genomics, Curve Biosciences, Universal Dx, ImCare, Mursla, and OmicXHealth
EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.
